Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Viking Therapeutics Inc (NASDAQ: VKTX) was $29.83 for the day, down -3.43% from the previous closing price of $30.89. In other words, the price has decreased by -$3.43 from its previous closing price. On the day, 3.25 million shares were traded. VKTX stock price reached its highest trading level at $31.07 during the session, while it also had its lowest trading level at $29.82.
Ratios:
Our analysis of VKTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 33.09 and its Current Ratio is at 33.09. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on February 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $102.
On February 07, 2025, Citigroup started tracking the stock assigning a Neutral rating and target price of $38.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Lian Brian sold 194,490 shares for $42.75 per share. The transaction valued at 8,313,601 led to the insider holds 2,366,570 shares of the business.
Mancini Marianna sold 54,215 shares of VKTX for $2,317,599 on Jan 06 ’25. The Chief Operating Officer now owns 374,134 shares after completing the transaction at $42.75 per share. On Jan 06 ’25, another insider, ZANTE GREG, who serves as the Chief Financial Officer of the company, sold 50,309 shares for $42.75 each. As a result, the insider received 2,150,595 and left with 165,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 3348357888 and an Enterprise Value of 2446859264.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.71, which has changed by -0.5423443 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $89.10, while it has fallen to a 52-week low of $24.41. The 50-Day Moving Average of the stock is -7.93%, while the 200-Day Moving Average is calculated to be -41.64%.
Shares Statistics:
VKTX traded an average of 4.60M shares per day over the past three months and 4720460 shares per day over the past ten days. A total of 111.57M shares are outstanding, with a floating share count of 108.95M. Insiders hold about 2.94% of the company’s shares, while institutions hold 73.73% stake in the company. Shares short for VKTX as of 1740700800 were 23912963 with a Short Ratio of 5.20, compared to 1738281600 on 23930853. Therefore, it implies a Short% of Shares Outstanding of 23912963 and a Short% of Float of 28.54.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Viking Therapeutics Inc (VKTX) in the stock market is under the watchful eye of 11.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.19 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$0.98 and -$2.16 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$2.12, with 14.0 analysts recommending between -$1.4 and -$3.1.
